Green Cross Cell Corp (031390):企業の財務・戦略的SWOT分析

◆英語タイトル:Green Cross Cell Corp (031390) - Financial and Strategic SWOT Analysis Review
◆商品コード:GDPH81983FSA
◆発行会社(調査会社):GlobalData
◆発行日:2021年1月
◆ページ数:41
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:韓国
◆産業分野:Pharmaceuticals and Healthcare
◆販売価格オプション(消費税別)
Site License(同一事業所内共有可)USD250 ⇒換算¥28,500見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD375 ⇒換算¥42,750見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Green Cross Cell Corp (031390) – Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
The profile contains critical company information including:

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Green Cross Cell Corp (GC Cell), a subsidiary of Green Cross Corp, is a provider of immunotherapeutics for the treatment of cancer. The company offers Immuncell-LC, an anti-cancer immune therapeutic that is derived from lymphocytes of cancer patient. It offers cryopreservation of cord blood that contains stem cells, which can be used to treat various diseases such as pediatric cancer, leukemia, stroke, diabetes, and liver diseases, among others. GC Cell offers contract services ranging from manufacturing of the biopharmaceuticals, processing, cell storage, and consulting, to the product delivery. The company also carries out research programs targeted at the treatment of leukemia, pancreatic cancer, ovarian cancer, acquired immunodeficiency syndrome (AIDS) and glioblastoma. GC Cell is headquartered in Seoul, South Korea.

Green Cross Cell Corp Key Recent Developments

Dec 02,2020: GC Green Cross recruits executive director Jo Jung-rae as new head of business management
Nov 12,2020: GC Green Cross launches’Bmax Ever’, a high-content active vitamin for the elderly
Nov 02,2020: GC Green Cross, 3rd quarter sales of 420 billion won, the highest ever
Oct 28,2020: GC Green Cross Lab Cell, 3Q sales and operating profit record
Oct 20,2020: GC Green Cross Medical Foundation appoints Chairman Eunhee Lee

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

【レポートの目次】

Table of Contents
List of Tables
List of Figures
Section 1 – About the Company
Green Cross Cell Corp – Key Facts
Green Cross Cell Corp – Key Employees
Green Cross Cell Corp – Major Products and Services
Green Cross Cell Corp – History
Green Cross Cell Corp – Locations And Subsidiaries
Head Office
Section 2 – Company Analysis
Company Overview
Green Cross Cell Corp – Business Description
R&D Overview
Green Cross Cell Corp – Corporate Strategy
Green Cross Cell Corp – SWOT Analysis
SWOT Analysis – Overview
Green Cross Cell Corp – Strengths
Green Cross Cell Corp – Weaknesses
Green Cross Cell Corp – Opportunities
Green Cross Cell Corp – Threats
Green Cross Cell Corp – Key Competitors
Section 3 – Company Financial Ratios
Financial Ratios – Capital Market Ratios
Financial Ratios – Annual Ratios
Performance Chart
Financial Performance
Financial Ratios – Interim Ratios
Financial Ratios – Ratio Charts
Section 4 – Company’s Lifesciences Financial Deals and Alliances
Green Cross Cell Corp, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Green Cross Cell Corp, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
Green Cross Cell Corp, Recent Deals Summary
Section 5 – Company’s Recent Developments
Dec 02, 2020: GC Green Cross recruits executive director Jo Jung-rae as new head of business management
Nov 12, 2020: GC Green Cross launches’Bmax Ever’, a high-content active vitamin for the elderly
Nov 02, 2020: GC Green Cross, 3rd quarter sales of 420 billion won, the highest ever
Oct 28, 2020: GC Green Cross Lab Cell, 3Q sales and operating profit record
Oct 20, 2020: GC Green Cross Medical Foundation appoints Chairman Eunhee Lee
Sep 08, 2020: GC Green Cross launches Korea’s only translucent acyclovir cream
Sep 04, 2020: Ubicare acquires a domestic patent for monitoring technology for suspected infectious diseases
Jul 30, 2020: GC Green Cross recorded 360 billion won in sales and 15.6 billion won in operating profit in the second quarter
Jul 30, 2020: UBI Care recorded 26.1 billion won in sales in the second quarter
Section 6 – Appendix
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

List of Tables
Green Cross Cell Corp, Key Facts
Green Cross Cell Corp, Key Employees
Green Cross Cell Corp, Major Products and Services
Green Cross Cell Corp, History
Green Cross Cell Corp, Key Competitors
Green Cross Cell Corp, Ratios based on current share price
Green Cross Cell Corp, Annual Ratios
Green Cross Cell Corp, Annual Ratios (Cont...1)
Green Cross Cell Corp, Annual Ratios (Cont...2)
Green Cross Cell Corp, Interim Ratios
Green Cross Cell Corp, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Green Cross Cell Corp, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
Green Cross Cell Corp, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

★海外企業調査レポート[Green Cross Cell Corp (031390):企業の財務・戦略的SWOT分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Mitsubishi Corporation:企業の戦略・SWOT・財務分析
    Mitsubishi Corporation - Strategy, SWOT and Corporate Finance Report Summary Mitsubishi Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • Shree Renuka Sugars Ltd (RENUKA):企業の財務・戦略的SWOT分析
    Shree Renuka Sugars Ltd (RENUKA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and wea …
  • Thermax Ltd (THERMAX):企業の財務・戦略的SWOT分析
    Thermax Ltd (THERMAX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Candela Corp:企業の戦略的SWOT分析
    Candela Corp - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. …
  • Miltenyi Biotec GmbH:医療機器:M&Aディール及び事業提携情報
    Summary Miltenyi Biotec GmbH (Miltenyi) is a biotechnology company that offers biomedical research and cellular therapy products for cell isolation, flow cytometry, sample preparation and cell culture. The company offers sample preparation, cell separation, flow cytometry, cell culture and stimulati …
  • University of Florida-製薬・医療分野:企業M&A・提携分析
    Summary University of Florida (UF) is an educational institute that offers undergraduate, graduate and distance learning programs. The institute offers educational programs in areas of agricultural, business administration, journalism and communications, law, dentistry, arts and sciences, medicine, …
  • 3M Co (MMM):医療機器:M&Aディール及び事業提携情報
    Summary 3M Company (3M) is a diversified technology company that specializes in the development, manufacture and marketing of a wide range of innovative products. The company develops technology platforms, including adhesives, abrasives, light management, microreplication, non woven materials, nanot …
  • Curevac AG-製薬・医療分野:企業M&A・提携分析
    Summary Curevac AG (Curevac), formerly CureVac GmbH is a clinical stage biopharmaceutical company that develops RNA-based medicines. The company designs, develops and produces messenger RNA molecules for therapeutic and prophylactic vaccines in the fields of oncology and infectious diseases. Its RNA …
  • Avadel Pharmaceuticals Plc (AVDL):医療機器:M&Aディール及び事業提携情報
    Summary Avadel Pharmaceuticals Plc (Avadel), formerly Flamel Technologies SA is a specialty pharmaceutical company, which develops and commercializes drugs for allergy, asthma, central nervous system (CNS) (narcolepsy), pain, respiratory diseases and diabetes. The company’s products are built on its …
  • TapImmune Inc (TPIV):企業の財務・戦略的SWOT分析
    Summary TapImmune Inc (TapImmune) is a clinical-stage immuno-oncology company focus on the development of innovative peptide, gene-based immunotherapeutics and vaccines for the treatment of cancer and metastatic disease. The company’s pipeline products include TPIV 200, which is intended for the tre …
  • Danaher Corporation:企業の戦略・SWOT・財務情報
    Danaher Corporation - Strategy, SWOT and Corporate Finance Report Summary Danaher Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • Grupo Televisa, S.A.B. (TLEVISACPO):企業の財務・戦略的SWOT分析
    Grupo Televisa, S.A.B. (TLEVISACPO) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …
  • Tosk Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Tosk Inc (Tosk) is a drug developing company that provides development of safety and efficacy conditions of drugs. The company discovers and develops new drugs for cancer and other conditions using non-mammalian animal species as models for human diseases. It provides optimizing marketed dru …
  • Statewide Superannuation Pty Ltd:企業の戦略的SWOT分析
    Statewide Superannuation Pty Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major pr …
  • Goldman Sachs Group Inc:戦略・SWOT・企業財務分析
    Goldman Sachs Group Inc - Strategy, SWOT and Corporate Finance Report Summary Goldman Sachs Group Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • Corporation Bank:企業の戦略・SWOT・財務情報
    Corporation Bank - Strategy, SWOT and Corporate Finance Report Summary Corporation Bank - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • Scripps Networks Interactive, Inc.:企業のM&A・事業提携・投資動向
    Scripps Networks Interactive, Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Scripps Networks Interactive, Inc. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on m …
  • Shilpa Medicare Ltd (SHILPAMED):製薬・医療:M&Aディール及び事業提携情報
    Summary Shilpa Medicare Ltd (Shilpa Medicare) focuses on the development, manufacture and commercialization of generic pharmaceutical products and active pharmaceutical ingredients (APIs). It offers medicines for the treatment of cancer, infectious diseases such as HIV, multiple sclerosis and immuno …
  • Actuated Medical Inc:医療機器:M&Aディール及び事業提携情報
    Summary Actuated Medical Inc (Actuated Medical) is a medical device company that develops minimally invasive instruments. The company provides products such as controlled tissue penetration systems, occlusion clearing systems and MRI compatible systems. Its controlled tissue penetration systems use …
  • Marr S.P.A.:企業の戦略・SWOT・財務分析
    Marr S.P.A. - Strategy, SWOT and Corporate Finance Report Summary Marr S.P.A. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate act …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆